Abstract: Crystalline base of compound trans-1-((1R,3S)-6-chloro-3-phenylindan-1-yl)-3,3-dimethylpiperazine, processes for the preparation of purified free base or salts of this compound, pharmaceutical compositions comprising the base and medical use thereof, including for treatment of schizophrenia and other psychotic disorders.
Type:
Grant
Filed:
December 1, 2009
Date of Patent:
May 28, 2013
Assignee:
H. Lunbeck A/S
Inventors:
Benny Bang-Andersen, Heidi Lopez de Diego
Abstract: This invention is directed to compounds which are selective antagonists for melanin concentrating hormone-1 (MCH1) receptors. The invention provides a pharmaceutical composition comprising a therapeutically effective amount of the compound of the invention and a pharmaceutically acceptable carrier. This invention provides a pharmaceutical composition made by combining a therapeutically effective amount of the compound of this invention and a pharmaceutically acceptable carrier. This invention further provides a process for making a pharmaceutical composition comprising combining a therapeutically effective amount of the compounds of the invention and a pharmaceutically acceptable carrier. This invention also provides a method of reducing the body mass of a subject which comprises administering to the subject an amount of a compound of the invention effective to reduce the body mass of the subject.
Type:
Grant
Filed:
July 3, 2003
Date of Patent:
January 6, 2009
Assignee:
H. Lunbeck A/S
Inventors:
Mohammad R. Marzabadi, Yu Jiang, Kai Lu, Chien-An Chen, John E. De Leon, John Wetzel
Abstract: This invention is directed to bicyclic and tricyclic compounds which are selective antagonists for NPY (Y5) receptors. The invention provides a pharmaceutical composition comprising a therapeutically effective amount of a compound of the invention and a pharmaceutically acceptable carrier. This invention provides a pharmaceutical composition made by combining a therapeutically effective amount of a compound of this invention and a pharmaceutically acceptable carrier. The invention provides a process for making a pharmaceutical composition comprising combining a therapeutically effective amount of a compound of the invention and a pharmaceutically acceptable carrier. This invention further provides the use of a compound of the invention for the preparation of a pharmaceutical composition for treating an abnormality, wherein the abnormality is alleviated by decreasing the activity of a human Y5 receptor.
Type:
Grant
Filed:
January 20, 2005
Date of Patent:
September 25, 2007
Assignees:
H. Lunbeck A/S, Novartis AG
Inventors:
Mohammad R. Marzabadi, Wai C. Wong, Stewart A. Noble, Yasuchika Yamaguchi
Abstract: Specific 6-substituted or 2-alkyl substituted indole or 2,3-dihydroindole compounds are provided, having long lasting serotonin activity with specific binding to 5-HT.sub.2 receptors of the central nervous system. These compounds are suitable for therapeutic treatment of CNS disorders, such as anxiety, depression, sleep disturbances, migraine, negative symptoms of schizophrenia, and Parkinson's disease.
Type:
Grant
Filed:
June 27, 1991
Date of Patent:
June 1, 1993
Assignee:
H. Lunbeck A/S
Inventors:
Jens K. Perregaard, Kim Andersen, Klaus P. Boegesoe, Henrik Pedersen